Home › Compare › YDWAF vs ABBV
YDWAF yields 9.73% · ABBV yields 3.06%● Live data
📍 YDWAF pulled ahead of the other in Year 1
Combined, YDWAF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YDWAF + ABBV for your $10,000?
Yodogawa Steel Works, Ltd. manufactures and sells steel products for industrial and consumer products in Japan. The company offers steel sheets products comprising pre-painted and galvanized steel sheets, chromate-free treated steel sheets, cold rolled steel strips, special steel strips, steel strapping, and cold rolled steel sheets, as well as plated steel sheets, colored plated and printed steel sheets, and other types of steel sheets. It also provides exterior products for storage sheds, garages, carports, bicycle parks, warehouses, lodges, and trash bins; and building materials comprising roofing and siding, and environmental products. In addition, the company offers rolls for section steel, including plate and hot strip mill work rolls; paper manufacturing rolls; drilled rolls for rubber and vinyl; calendar equipment for paper making; and cast iron rollers and other types of rollers. Further, it provides high-function grating products, as well as other gratings products, including grating, and pit and U-shaped covers. Additionally, the company is involved in the design and contracting of construction work; warehousing, packaging, and shipping activities; and sale, purchase, and lease of real estate, as well as building of facilities and landscaping activities. Yodogawa Steel Works, Ltd. was incorporated in 1935 and is headquartered in Osaka, Japan.
Full YDWAF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.